EMAN RESEARCH PUBLISHING | <p>Homocysteine and Visfatin Upregulation for Type 2 Diabetes Etiology</p>

Inflammation Cancer Angiogenesis Biology and Therapeutics | Impact 0.1 (CiteScore) | Online ISSN 2207-872X

RESEARCH ARTICLE (Open Access)

Homocysteine and Visfatin Upregulation for Type 2 Diabetes Etiology

Sabaa Ahmed ¹, Abdul-Rahim A. Ali ², Murooj G. Jameel ^2*, Mayada Talal Hamoo ², Mohammed fawzi majeed ², Dina Suhail M Saleh ², Sarah Hussain Khalaf ²

+ Author Affiliations

Journal of Angiotherapy 8 (4) 1-6 https://doi.org/10.25163/angiotherapy.849539

Submitted: 29 January 2024 Revised: 04 April 2024 Published: 07 April 2024

Abstract

Background: Diabetes is a metabolic disorder characterized by insulin dysfunction. It has seen a surge in prevalence in recent years. Understanding the factors influencing diabetes pathogenesis is crucial for developing effective treatments. Recent studies have identified visfatin as a hormone with insulin-like properties, highlighting its potential role in diabetes. Methods: This study aimed to investigate the levels of homocysteine and its association with visfatin in diabetic patients compared to healthy individuals. Thirty patients with type 2 diabetes were enrolled, and their visfatin and homocysteine levels were measured. Results: Our findings revealed elevated levels of homocysteine and visfatin in diabetic patients compared to the control group. Statistical analysis demonstrated a significant difference between the two groups (P < 0.05). Furthermore, we observed a correlation between Apo.A1, Apo.B, and Apo.B / ApoA1 with visfatin and homocysteine levels, indicating a direct and significant relationship between visfatin levels and these apolipoproteins. Conclusion: The study underscores the importance of visfatin and homocysteine in diabetes pathophysiology. Elevated levels of these biomarkers in diabetic patients suggest their potential role as indicators or contributors to the disease. Further research into the mechanisms underlying their interaction may offer insights into novel therapeutic approaches for diabetes management.

Keywords: Diabetes mellitus, Homocysteine, Visfatin, Apolipoproteins, Case-control study

References

Abel Lo´ pez-Bermejo, Berta Chico-Julia`, et al. (2006). Serum Visfatin Increases With Progressive beta-Cell Deterioration. Diabetes, 55(10), 2871–2875.

Adeghate, E. (2004). An update on the biology and physiology of resistin. Cell Mol Life Sci, 61(19-20), 2485-96.

Adeghate, E., Schattner, P., & Dunn, E.J.A.o.t.N.Y.a.o.s. (2006). An update on the etiology and epidemiology of diabetes mellitus. 1084(1), 1-29.

Amos, A., McCarty, D., & Zimmet, P. (1997). Diabet Med 14 Suppl 5, S1.

Ansari, R., et al. (2014). Hyperhomocysteinemia and neurologic disorders: a review, 10(4), 281-288.

Ansari, T., et al. (2020). Frequency of elevated plasma homocysteine (Hcy) levels among type 2 Diabetes mellitus (T2DM) patients, 27(03), 635-640.

Chen Miao-Pei et al. (2006). Elevated Plasma Level of Visfatin/Pre-B Cell Colony Enhancing Factor in Patients with Type 2 Diabetes Mellitus. J Clin Endocrinol Metab, 91(1), 295–299.

Curat, C., et al. (2006). Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin. 49(4), 744-747.

de Marco R., Locatelli F., Zoppini G., Verlato G., Bonora E., Muggeo M. (1999). Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care, 22, 756–761.

Henrieta Škovierová et al. (2016). The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. Int. J. Mol. Sci., 17, 1733.

Kumar, J., et al. (2015). No evidence of a causal relationship between plasma homocysteine and type 2 diabetes: a Mendelian randomization study. 2, 11.

Laudes M, Oberhauser F, Schulte DM, Freude S, Bilkovski R, Mauer J, Rappl G, Abken H, Hahn M, Schulz O, Krone W. (2010). Visfatin/PBEF/Nampt and resistin expressions in circulating blood monocytes are differentially related to obesity and type 2 diabetes in humans. Horm Metab Res, 42, 268–273.

M A Pajares and D Pérez-Sala. (2006). Betaine homocysteine S-methyltransferase: just a regulator of homocysteine metabolism?. Cell Mol Life Sci, 63(23), 2792-803.

Marti-Carvajal, A.J., et al. (2017). Homocysteine-lowering interventions for preventing cardiovascular events, 8.

Mona Mohamed Ibrahim Abdalla Abdalla MMI. (2022). Role of visfatin in obesity-induced insulin resistance. World J Clin Cases, 10(30), 10840-10851.

Murooj G Jameel, Zainab M. Hashim, & Mohammad H. Al-Osami. (2022). Prevalence of AGER Gene Polymorphism in Post Menopause Iraqi Sample with Osteoporosis and Osteopenia in type 2Diabetes Mellitus. raqi J Pharm Sci, 31(2).

Mursleen, M.T., et al. (2017). Implication of homocysteine in diabetes and impact of folate and vitamin B12 in diabetic population. 11, S141-S146.

Roivainen, M., et al. (1998). Several different enterovirus serotypes can be associated with prediabetic autoimmune episodes and onset of overt IDDM. 56(1), 74-78.

Townsend, T.J.I.J.o.D., & Metabolism, A decade of diabetes research and development. (2000). 8, 88-92.

Tsutomu Hirano. (2018). Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb, 25(9), 771-782.

Yanling Wu1, Yanping Ding, Yoshimasa Tanaka and Wen Zhang. (2014). Risk Factors Contributing to Type 2 Diabetes and Recent Advances in the Treatment and Prevention. Int. J. Med. Sci., 11.

Yoon, K.-H., et al. (2006). Epidemic obesity and type 2 diabetes in Asia. 368(9548), 1681-1688.

Abstract
Export Citation

View Dimensions

View Plumx

View Altmetric

Save

0
Citation

42
View

Share